[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE602004026106D1 - Injizierbares implantat mit verzögerter freisetzung mit einem bioerodierbaren matrixkern und einer bioerodierbaren haut - Google Patents

Injizierbares implantat mit verzögerter freisetzung mit einem bioerodierbaren matrixkern und einer bioerodierbaren haut

Info

Publication number
DE602004026106D1
DE602004026106D1 DE602004026106T DE602004026106T DE602004026106D1 DE 602004026106 D1 DE602004026106 D1 DE 602004026106D1 DE 602004026106 T DE602004026106 T DE 602004026106T DE 602004026106 T DE602004026106 T DE 602004026106T DE 602004026106 D1 DE602004026106 D1 DE 602004026106D1
Authority
DE
Germany
Prior art keywords
drug
skin
core
polymer
bioerodic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004026106T
Other languages
English (en)
Inventor
Kang-Jye Chou
Hong Guo
Paul Ashton
Robert W Shimizu
David A Watson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals Inc
Eyepoint Pharmaceuticals US Inc
Original Assignee
Psivida US Inc
Psivida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/714,549 external-priority patent/US8871241B2/en
Application filed by Psivida US Inc, Psivida Inc filed Critical Psivida US Inc
Publication of DE602004026106D1 publication Critical patent/DE602004026106D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Prostheses (AREA)
DE602004026106T 2003-11-13 2004-10-26 Injizierbares implantat mit verzögerter freisetzung mit einem bioerodierbaren matrixkern und einer bioerodierbaren haut Expired - Lifetime DE602004026106D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/714,549 US8871241B2 (en) 2002-05-07 2003-11-13 Injectable sustained release delivery devices
US54336804P 2004-02-09 2004-02-09
PCT/US2004/035430 WO2005051234A2 (en) 2003-11-13 2004-10-26 Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin

Publications (1)

Publication Number Publication Date
DE602004026106D1 true DE602004026106D1 (de) 2010-04-29

Family

ID=34636703

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004026106T Expired - Lifetime DE602004026106D1 (de) 2003-11-13 2004-10-26 Injizierbares implantat mit verzögerter freisetzung mit einem bioerodierbaren matrixkern und einer bioerodierbaren haut

Country Status (20)

Country Link
EP (2) EP2233112B3 (de)
JP (3) JP5661226B2 (de)
AT (1) ATE460901T1 (de)
AU (1) AU2004292957C1 (de)
CA (1) CA2545650C (de)
CY (1) CY1114947T1 (de)
DE (1) DE602004026106D1 (de)
DK (1) DK1696822T3 (de)
ES (2) ES2447816T7 (de)
FR (1) FR14C0042I1 (de)
HK (1) HK1148931A1 (de)
IL (1) IL175584A (de)
MX (1) MXPA06005431A (de)
NO (1) NO20062362L (de)
NZ (3) NZ547619A (de)
PL (2) PL2233112T6 (de)
PT (2) PT2233112E (de)
SI (1) SI1696822T1 (de)
TW (2) TWI496597B (de)
WO (1) WO2005051234A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
NZ547619A (en) 2003-11-13 2009-06-26 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
EP2377569A1 (de) 2004-07-02 2011-10-19 QLT Plug Delivery, Inc. Behandlungsmittelspender und Verfahren zur Abgabe des Behandlungsmittels an das Auge
US20070149593A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US8795711B2 (en) 2006-03-31 2014-08-05 Mati Therapeutics Inc. Drug delivery methods, structures, and compositions for nasolacrimal system
UA97971C2 (ru) 2007-06-08 2012-04-10 Берингер Ингельхайм Интернациональ Гмбх Препарат невирапина пролонгированного высвобождения
NZ583858A (en) 2007-09-07 2012-08-31 Quadra Logic Tech Inc Lacrimal implant detection with detection device
FR2927798B1 (fr) * 2008-02-25 2011-03-04 C L Investissements Procede de fabrication d'un dispositif contraceptif intra-uterin et installation pour la mise en oeuvre de ce procede
US8858983B2 (en) 2009-04-30 2014-10-14 Medtronic, Inc. Antioxidants and antimicrobial accessories including antioxidants
EP2515864A4 (de) * 2009-12-23 2013-09-11 Psivida Inc Vorrichtung mit verzögerter freisetzung
AU2011237788A1 (en) * 2010-04-06 2012-11-01 Allergan, Inc. Sustained-release reservoir implants for intracameral drug delivery
EP2571526B1 (de) 2010-05-17 2019-03-13 Novaer Holdings, Inc. Wirkstofffreisetzungsvorrichtungen zur freisetzung okularer therapeutischer wirkstoffe
US8911427B2 (en) 2010-12-28 2014-12-16 Medtronic, Inc. Therapeutic agent reservoir delivery system
AU2012214146A1 (en) * 2011-02-11 2013-08-29 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
DK2750660T3 (en) 2011-08-29 2016-12-12 Mati Therapeutics Inc FILING WITH PROLONGED RELEASE OF ACTIVE AGENTS to treat glaucoma and ocular hypertension
EP2750666B1 (de) 2011-08-30 2017-10-04 Universiteit Gent Mehrschichtige formulierungsfreisetzung
CN104271171A (zh) * 2012-05-30 2015-01-07 波士顿科学医学有限公司 用于受控的治疗剂释放的可注射生物可降解颗粒
JP6720447B2 (ja) 2014-12-18 2020-07-08 ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ． 酸感受性薬剤の送達のための薬剤送達系
US11298323B2 (en) * 2017-06-13 2022-04-12 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices
FR3085841B1 (fr) * 2018-09-14 2020-12-04 Oreal Procede de preparation de capsules et systeme associe
EP3698841A1 (de) * 2019-02-19 2020-08-26 L'oreal Injektionsvorrichtung
CA3171147A1 (en) * 2020-03-17 2021-09-23 Nannaji Saka Expandable, multi-excipient structured dosage form for prolonged drug release

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US5091185A (en) * 1990-06-20 1992-02-25 Monsanto Company Coated veterinary implants
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5550050A (en) * 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5486328A (en) 1994-05-31 1996-01-23 Randcastle Extrusion Systems, Inc. Extrusion surge suppressor and method
US5518672A (en) 1994-05-31 1996-05-21 Randcastle Extrusion Systems, Inc. Extrusion surge controller and method
US5569429A (en) 1995-05-05 1996-10-29 Randcastle Extrusion Systems, Inc. Dynamic seal and sealing method
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
SE0001893D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab Medical arrangement
JP2004535431A (ja) * 2001-06-22 2004-11-25 サザン バイオシステムズ， インコーポレイテッド ゼロ次長期放出同軸インプラント
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
AUPR951501A0 (en) * 2001-12-14 2002-01-24 Smart Drug Systems Inc Modified sustained release pharmaceutical system
EP1458352A1 (de) * 2001-12-18 2004-09-22 Novo Nordisk A/S Festdosis-mikroimplantat
NZ547619A (en) 2003-11-13 2009-06-26 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin

Also Published As

Publication number Publication date
PL1696822T3 (pl) 2010-08-31
NZ547619A (en) 2009-06-26
EP2233112B1 (de) 2013-11-20
WO2005051234A2 (en) 2005-06-09
FR14C0042I1 (fr) 2014-06-27
ATE460901T1 (de) 2010-04-15
EP2233112A2 (de) 2010-09-29
CY1114947T1 (el) 2016-12-14
CA2545650A1 (en) 2005-06-09
JP2012072180A (ja) 2012-04-12
SI1696822T1 (sl) 2010-07-30
PL2233112T3 (pl) 2014-05-30
EP2233112B3 (de) 2014-05-14
EP1696822B1 (de) 2010-03-17
NO20062362L (no) 2006-08-13
NZ581461A (en) 2011-04-29
PT1696822E (pt) 2010-04-28
TW201422269A (zh) 2014-06-16
CA2545650C (en) 2015-08-18
WO2005051234A3 (en) 2005-11-10
PT2233112E (pt) 2014-02-27
TW200526285A (en) 2005-08-16
ES2340389T3 (es) 2010-06-02
EP1696822A2 (de) 2006-09-06
IL175584A0 (en) 2006-09-05
IL175584A (en) 2015-05-31
JP5526114B2 (ja) 2014-06-18
ES2447816T3 (es) 2014-03-13
AU2004292957B2 (en) 2010-09-09
DK1696822T3 (da) 2010-05-17
AU2004292957C1 (en) 2011-04-28
JP5918195B2 (ja) 2016-05-18
TWI496597B (zh) 2015-08-21
AU2004292957A1 (en) 2005-06-09
EP2233112A3 (de) 2011-03-02
MXPA06005431A (es) 2007-01-25
NZ575950A (en) 2010-06-25
JP5661226B2 (ja) 2015-01-28
HK1148931A1 (en) 2011-09-23
TWI445559B (zh) 2014-07-21
ES2447816T7 (es) 2014-06-25
PL2233112T6 (pl) 2014-11-28
JP2007512248A (ja) 2007-05-17
JP2014040479A (ja) 2014-03-06

Similar Documents

Publication Publication Date Title
IL175584A (en) Devices for delayed injection material release
AU651084B2 (en) Article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances
DE69929055T2 (de) Verfahren zur spritzgussherstellung von vorrichtungen mit kontrollierter wirkstofffreisetzung und damit hergestellte vorrichtung
DE60017956D1 (de) Biodegradierbare polymerzusammensetzung
WO2011012137A3 (en) A medical device of polyolefin
EP1129731A3 (de) Zusammensetzungen, Verfahren und Methoden zur Verbesserung der Abriebfestigkeit von prothetischen medizinischen Artikeln
DE50103340D1 (de) Verfahren zur herstellung aktivstoffhaltiger kapseln mit ultradünner wandschicht
WO2009079507A3 (en) Crosslinked hydrogels
Alkhalaf et al. Review of polydimethylsiloxane (pdms) as a material for additive manufacturing
DE602004014496D1 (de) Verwendung von ethanol als weichmacher zur herstellung von subkutanen implantaten , welche in einer plga matrize dispergierte thermolabile wirkstoffe enthalten
DE69629378D1 (de) Röhrenförmige tamponeinführhilfe und zugehöriges herstellungsverfahren mit hilfe einer weichen, flexiblen zusammensetzung
IN2012DN04939A (de)
ATE240205T1 (de) Verfahren zur entformung eines durchsichtigen gegenstandes und dessen anwendung zur herstellung eines gegenstandes aus durchsichtigem kunststoff wie z.b. einer kontaktlinse
EP2558271B1 (de) Kanülenvorrichtung und verfahren und vorrichtung zum bestücken einer kanülenvorrichtung mit einem implantat
Govender et al. 3D bioprinted microneedles: merging drug delivery and scaffold science for tissue-specific applications
WO2006084211A3 (en) Thermoplastic articles containing a medicament
CY1114534T1 (el) Συσκευες ενεσιμης χορηγησης με παρατεταμενη αποδεσμευση
CA2116917A1 (en) Injection molded product and method
CN113400639A (zh) 一种ecm水凝胶与交联剂混合的三维打印方法
EP2072216A3 (de) Verfahren und Vorrichtung zur Herstellung von optischen Artikeln
CN1209169C (zh) 医用外科固定材料及其制备方法
GB2300590A (en) Powder injection moulding and extrusion
KR20160048741A (ko) 조직 수복용 물질 및 이를 구비하는 조직 수복용 장치
TW200500094A (en) Sustained release dosage forms of anesthetics for pain management

Legal Events

Date Code Title Description
8364 No opposition during term of opposition